The COVID-19 outbreak is gripping our planet like no other health crisis in recent history. Overt collaboration and policy action are required to meet this challenge and, as importantly, prepare for the future. Elevating and prioritizing the interconnectedness of living things through One Health strategies and modernizing Americas animal biotechnology regulatory approach are two policies Congress and the White House must confront. In fact, they are long overdue.

Sixty percent of human diseases begin in animals.Scientists are confident that the COVID outbreak originated in batsand then was spread through another animal and then to humans, like the 2002-03 SARS outbreak. As the climate changes and populations grow and move, these zoonotic diseases will become more prevalent and potentially more dangerous.

Aside from the dreadful health implications, the resulting economic costs of a pandemic are profound.The World Bank estimates that, between 1997 and 2009, the global costs from six zoonotic outbreaks exceeded $80 billion. While we wont know the total impact for some time, COVID-19 has already producedone of the sharpest economic downturns in U.S. history and is costing the U.S. treasury alone trillions of dollars.

Society was woefully unprepared for this pandemic. We must employ modern approaches to be ready for future outbreaks. One Health collaboration eliminates barriers that often exist between human health, animal health, and environmental health strategies to create smarter, multi-faceted and coordinated efforts.

BIO supports legislation such as the Advancing Emergency Preparedness Through One Health Act of 2019. This bill would direct the U.S. Department of Health and Human Services and the U.S. Department of Agriculture (USDA) to coordinate with other agencies and state and local leaders to advance a national One Health framework to better prevent, prepare for, and respond to zoonotic disease outbreaks like COVID-19. Congress and the White House must factor One Health into their efforts to address future pandemics.

Animal health and wellness is a critical component of One Health strategy. To help the U.S. better prepare for the future, we need changes to the U.S. animal biotechnologyregulatory system.The U.S. governments current approach to regulating animal biotechnology as a new animal drug has all but destroyed investment and blocked market access for a host of beneficial products.

Biotechnology, for example, could armpigs with resistanceto African Swine Fever. Similarly,scientists have developed achickenthat is resistant to contracting and transmitting avian influenza.

Other innovations in animal biotechnology may be able prevent, prepare for, and respond to outbreaks of infectious diseases such as coronavirus, Ebola, MERS, Zika, among others, by providing prevention strategies andtreatments for humans.

Unfortunately, the United States regulatory system for animal biotechnology is not appropriately science- or risk-based, and as a result we are falling behind other countries, such as Brazil, where innovative start-ups are finding more support.

Indeed, despite decades of animal biotechnology research and advances, only one biotech food animal has been approved to date the AquaBounty salmon which languished in the U.S. regulatory system for more than two decades and still has not hit the market because ofpolitical interference.

The current crisis underscores the urgent need to break down roadblocks to progress.

BIO is calling on the White House to direct the U.S. Food and Drug Administration (FDA) and the USDA to clarify within 30 days a plan to overhaul the current regulatory approval process for animal biotechnology.

In alettersent to the President, BIO implores the need for a new approach that 1) more appropriately draws upon existing legal authorities to safeguard animal health, food safety, and the environment; 2) incentivizes research and investment in the technology; and 3) ensures safe and affordable products reach consumers as soon as possible.

A joint agreement between both agencies will help farmers, innovators, and consumers realize the benefits that modern technology can bring to the United States and the world. And just may well prevent the next potential animal to human disease outbreak.

Dana OBrien,Executive Vice President,Food & AgricultureBiotechnology Innovation Organization (BIO)

See the article here:
Opinion: Coronavirus outbreak stresses need for One Health and animal biotech advancement - Agri-Pulse

The COVID-19 pandemic highlights the need for an overhaul of the government's regulatory system for animalbiotechnology products,the Biotechnology Innovation Organization said in a letter to President Donald Trump Tuesday.

The Food and Drug Administrations current approach to regulating all applications of this technology as a new animal drug should be replaced with a new model that more appropriately draws upon existing legal authorities to safeguard animal health, food safety, and the environment, BIO President and CEO Jim Greenwood said. BIO called on USDA and FDA to sign a Memorandum of Understanding within 30 days, a move endorsed by Ag Secretary Sonny Perdue in February.

Animal biotech researchers have been critical of FDAs approach, saying it is cumbersome and hinders the development of new technology.

In its one-page letter, BIO said COVID-19 highlights the interconnectedness of human, animal, and environmental health. While it would not have prevented the current pandemic, animal biotechnology holds enormous potential to safeguard society from future zoonotic diseases that frequently exact high economic and health costs, and to develop human therapeutics relevant to the current outbreak.

Zoonotic diseases are those that jump from animals to humans, as is suspected in the case of the novel coronavirus. In an opinion piece posted on the Agri-Pulse website Tuesday, BIO Executive Vice President for Food and Agriculture Dana OBrien said, As the climate changes and populations grow and move, these zoonotic diseases will become more prevalent and potentially more dangerous.

For more news, go to http://www.Agri-Pulse.com.

View post:
FDA, USDA need to reach agreement on animal biotech, BIO says - Agri-Pulse

While promoting hygiene through its products made up of waterless technology, Clensta International has created the first line of defence via shielding human beings from infection of viruses and bacteria, informs Dr Puneet Gupta, Founder and CEO, Clensta International, to Viveka RoyChowdhury

What is the impact of waterless technolgy on sanitation in the public health and sanitation sphere, against the backdrop of the coronavirus infection, which has been declared as a pandemic by the World Health Organization (WHO)?

To minimise the chances of infection and disease and thereby save many lives, we have developed the next generation tech-powered products which directly impact the common population. Besides promoting hygiene, they are also useful in inculcating a behavioural change towards the protection of the environment. This is in line with the Sustainable Development Goal (SDG 6) to ensure availability and sustainable management of water and sanitation for all.

As prevention is always better than cure, our products create the first line of defence via shielding human beings from infection of viruses and bacteria. Over the years, Clensta has been a driver of change to help and protect our loved ones by providing instant hygiene to anyone, anywhere and anytime.0 Hence, we conducted research to understand the new cleanliness regime and mindset. Interestingly, the findings reveal that 70 per cent of mothers believe cleaning is equivalent to germ-free. This waterless hand rub is an ideal offering to ensure cleanliness and underscores our commitment to maintaining a germ-free environment.

Why did you choose to focus on waterless technology for your entrepreneurial journey?

Of late, sustainability has become a new dimension for companies. There has been an emergence of startups working in the area of climate change mitigation and environmental protection. After working closely with the defence personnel, I gained an insight into their challenges. The challenge of not bathing for days, while on duty during extreme weather conditions at locations such as Siachin, Kargil or Drass motivated me towards developing waterless technology products leading to the establishment of Clensta International.

What are the important milestones in this entrepreneurial journey?

The year 2017 marked Clenstas association with IIT Delhi as our research and development centre. This was instrumental in not only providing R&D support, but it also served as a platform for new startups to implement innovative ideas. Another milestone was raising seed and pre-series A fund from Indian Angle Network and notable alumni of IIT Delhi. Clensta International has also received a grant from Biotechnology Industry Research Assistance Council (BIRAC) under BIG Scheme to scale up innovation.

We have also received an appreciation from the President of India Ram Nath Kovind, which boosted the motivation of the entire team. The overwhelming response towards the product truly indicates that people are increasingly becoming conscious of the need to protect the environment and are embracing innovation.

Are there similar products in other geographies?

Currently, there is no company working in the domain of waterless FMCG or personal hygiene space in India as extensively as we are. Hence, it can be said that ours is a one-of-a-kind concept of waterless hygiene products. Though some companies have launched waterless shampoo, we are perhaps the only organisation having waterless technology as the core idea.

What have been the sales and marketing strategies, the sales channels employed?

The marketing strategy plays an instrumental role in gaining a sustainable competitive advantage for the company. We follow a B2B sales channel wherein the product is sold via a distribution network. We deploy the right mix of channels and possess a team with in-depth expertise in healthcare marketing. Their expertise is also instilling a behavioural change towards the innovations. Of late, we have been leveraging digital marketing tools extensively, including social media platforms like Facebook and LinkedIn to connect with our target audience.

Which are the sectors that are being tapped?

Clensta International aims to promote personal hygiene while protecting the environment. The issue is largely unaddressed, especially in rural areas and urban slums. The water resources face unprecedented threat worldwide. Around 2.2 billion people do not have access to safe drinking water and 4.2 billion people lack access to adequate sanitation facilities. Hence, there is an urgent need to scale up innovation geared towards promoting efficiency in water use. If we were to talk about the healthcare sector, a patient undergoing surgery or a bed-ridden person may not bathe for days and survives in unhygienic conditions. Similarly, there is immense potential in the tourism sector as waterless products are handy for travellers. In the defence sector, soldiers deployed in extreme weather conditions such as Siachen does not have access to proper bathing facilities. Adventure enthusiasts and mountaineers too face this issue of poor hygiene. Hence, our products are relevant not only for healthcare, but also for travel and defence sectors.

How are these products being positioned to hospitals and clinics?

Clensta International is working on developing an innovative healthcare product line. Its current products waterless body bath and waterless shampoo cater to the home healthcare and hospital segments. Maintaining hygiene is of utmost importance for patients, especially those in critical situations to minimise the chances of any infection. It is here that our waterless technology comes to the rescue and provides the first line of defence against viruses and bacteria.

It is also noteworthy that alternative means of bathing such as sponging and wet towel bathing increase the chances of microbial load and transfer of bacteria and other viruses to the human body. Thus, our waterless technology comprising a simple formulation that is free of alcohol, SLS and any other harmful ingredients, is useful for maintaining basic hygiene and cleanliness. The products can be directly applied to hair and body, massaged and then can be dried off using a towel. These remove dirt, oil and grease completely. Thus, our innovative healthcare solution enables convenient, on-the-go and quick access to hygiene.

Have there been any studies done to prove that the use of such products decreases the incidence of hospital-acquired infection (HAI), also known as nosocomial infections?

Our product- Clensta Waterless Body Bath is anti-bacterial, antiseptic, and has been approved by the FDA as well as tested dermatologically. All products are being extensively used in defence, hospital and healthcare institutions. The product has also been put at trial at Madras Medical College, Multi- Super Specialty Hospital Tamil Nadu, SRM Institute of Medical Sciences and Indian Navy for antimicrobial testing.

How affordable are such products, given Indias disease burden due to infectious diseases?

Clensta International is continuously striving to make its products affordable through government support. Our products have been deemed for an essential use for the Indian Navy and will soon be a necessity for the Indian Army. We are making efforts to facilitate the availability of our products to the underprivileged section of the society through our Corporate Social Responsibility (CSR) initiative and by joining hands with various governmental institutes and hospitals. Our core idea to disseminate awareness on personal hygiene while protecting the environment is also being encouraged through our marketing strategy and social media awareness campaigns. With our CSR initiative, we are also educating children in rural areas on the significance of maintaining basic hygiene.

As a start-up, what are the policies and regulations which can spur further innovation?

It is commendable that the Indian government has undertaken various initiatives such as Start-up India, Skill India, etc to spur innovation and catalyse entrepreneurship. However, there is a scope of improvement in our existing intellectual property policy framework when it comes to addressing the issue of patent protection. Surely, in comparison to before, multiple processes have been implemented to ease the fund and grant approvals. Moreover, now, we could look forward to expediting the process of granting permissions by instituting a single-window clearance mechanism. Yet, the most daunting challenge ahead for start-ups is to minimise the go-to-market time for products and to attain a sustainable competitive advantage globally.

What are your plans for future products, overseas sales, etc.?

Our focus is to penetrate deeper into the Indian market and expand ourselves in tier II- and tier-III cities. We envision to establish ourselves as a leading player in the B2B space while exploring the possibilities of establishing ourselves in the B2C market as well. Expanding our footprints internationally is on the cards. We have already set up global operations with a subsidiary in The Netherlands and are further exploring business opportunities in Africa, Asia, the European Union, North America as well as South America. We aim to disrupt the biotechnology landscape with out of -the-box and innovative product line. We will be soon foraying into the homecare segment in an endeavour to provide sustainable solutions to Indian households while simultaneously reducing the consumption of plastic.

[emailprotected]

Excerpt from:
We aim to disrupt the biotechnology landscape with out out-of-the-box and innovative product line - Express Healthcare

Oncolytics Biotech, Inc. (ONCY) is around the top of the Biotechnology industry according to InvestorsObserver. ONCY received an overall rating of 85, which means that it scores higher than 85 percent of all stocks. Oncolytics Biotech, Inc. also achieved a score of 99 in the Biotechnology industry, putting it above 99 percent of Biotechnology stocks. Biotechnology is ranked 11 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 85 means the stock is more attractive than 85 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Oncolytics Biotech, Inc. (ONCY) stock is down -2.44% while the S&P 500 has risen 5.92% as of 2:02 PM on Monday, Apr 6. ONCY is down -$0.04 from the previous closing price of $1.45 on volume of 194,581 shares. Over the past year the S&P 500 is down -8.97% while ONCY is down -24.19%. ONCY lost -$1.05 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Oncolytics Biotech, Inc. click here.

Continue reading here:
Industry Breakdown: Where Does Oncolytics Biotech, Inc. (ONCY) Stock Fall in the Biotechnology Field? - InvestorsObserver

MIRAMAR, Fla., April 06, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) President & CEO Joseph Moscato offers an open letter to shareholders to provide an update on the companys response, operationally and scientifically.

Dear Generex Shareholders,

The emergence and rapid escalation of the COVID-19 pandemic has deeply impacted our lives as we never could have imagined. During these uncertain times the health and well-being of our Generex family, including our employees, shareholders, investors and partners is paramount. For the well-being of all of our stakeholders, we are committed to following the precautions of health advisors and adhering to suggestions, advice, and laws set up by local municipalities, cities, states, and the federal government to stop this pandemic that has disrupted the world. Generex Biotechnology remains dedicated to safeguarding your investment in GNBT as we continue working towards positive outcomes into the future through our strategic initiatives and development programs, including our previously announced efforts to develop a vaccine for the SARS-CoV-2 virus.

We want to take this time to update shareholders on the steps we are taking to efficiently manage the businesses of Generex and our subsidiaries through these challenging times. We are virtually fully operational with all our business management teams and their employees through video conference and are committed to following through with our short, mid and long-term goals and plans to add value for our shareholders.

As reported Generex has jumped into the vaccine race with its Ii-Key-COVID-19 Complete Vaccine, which is designed to activate both the cellular (CD4 and CD8 T cells) and humoral (antibody) immune responses. As previously reported, we have signed an agreement with a Chinese consortium to develop our Complete Vaccine for China. Since signing the agreement, Generex has developed and refined our vaccine plans and has invoiced the Chinese consortium for the upfront payment and licensing fee.

Generex has also partnered with EpiVax, a leader in computational vaccinology, that has developed algorithms to identify specific amino acid peptide sequences or epitopes that are predicted to activate the various cellular components of the immune system including CD4 T Cells, CD8 T Cells, and B Cells that produce antibodies. An additional advantage of their vaccinology algorithms is their ability to dehumanize peptide sequences to minimize autoimmune reactions. EpiVax has identified a series of epitopes of the SARS-CoV-2 viral proteins that may be used to produce a vaccine. Generex plans to manufacture laboratory scale amounts of the EpiVax peptides linked with our Ii-Key technology to screen against blood samples from patients who have recovered from COVID-19. We are in the process of identifying hospitals and research centers that can provide us with the blood samples for peptide epitope screening. We expect this screening process to yield the best 3 to 5 Ii-Key peptides that we anticipate will make the most safe and effective vaccine for human clinical trials.

To advance our vaccine development efforts, the team at Generex has been proactive in reaching out to a number of countries, and we have had productive conversations with several government officials, Ministries of Health, and other key influencers to describe our technology, our clinical strategy, potential manufacturing partners, and our rapid path to vaccination for their populations. Generex has also met and had discussions with U.S. government agencies to provide them with details of our Ii-Key peptide vaccine technology, and we are in discussions with the decision makers for federal funding and partnership. It has been a slow process, but we believe that vaccines are now getting more government attention as local, state, and federal officials recognize the severity of this pandemic and the likelihood that the virus will return next year.

Generex has identified a clinical research organization, regulatory consultants, and clinical research sites to conduct our trials, and we are working with our contract manufacturing partners for AE37 to produce our Ii-Key-SARS-CoV-2 peptide vaccine for human clinical trials and population vaccination initiatives. We are also in discussions with pharmaceutical companies to include their vaccine adjuvants as part of the clinical trial design to evaluate the potential of using adjuvant in our vaccine formulation.

Story continues

Generex is highly confident in our rapid vaccine development program and in our plans to scale the manufacturing of Ii-Key- SARS-CoV-2 peptide vaccines to conduct not only the clinical trials required to meet the approval standards of global regulatory authorities, but to meet government expectations for mass population vaccination.

In conclusion, while the COVID-19 pandemic is surely a fast evolving situation with multiple layers of complexity, we believe market conditions should ultimately favor long-term minded, value oriented, and fundamental investors. Generex has many subsidiaries and many assets, from its FDA-cleared wound care product Excellegen, to our development products in inflammatory bowel diseases, diabetes, infectious disease, and cancer, to our pending operations in Arizona, with the ultimate vision of building a HMO with, in our opinion, unprecedented benefit packages through our own products, devices, and ancillary services. Based on all these efforts and assets, it is my belief that Generex has the staying power to thrive and bring value to our shareholders. Rest assured, Generex is well equipped to navigate the current environment as we remain focused on our core competencies and businesses while positioning our high-value assets for the future.

In the immediate days ahead, we will continue working to solidify the development path and government partnerships to complete our Ii-Key-SARS-CoV-2 Complete Vaccine program so that we can make a difference not only for Generex, our employees, and our shareholders, but for the world. Finally, we thank you all for your continued support as we navigate through this difficult period together, and please everyone, stay safe, be well and take care of your families and friends.

Sincerely,Joe MoscatoCEO

About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 1-800-391-6755 Extension 222 investor@generex.com

Follow this link:
Generex Biotechnology CEO Offers an Open Letter to Shareholders and Provides an Update on Corporate Response to the COVID-19 Pandemic - Yahoo Finance

TEL AVIV, Israel, April 3, 2020 /PRNewswire/ -- Cellect BiotechnologyLtd. (Nasdaq: APOP), a developer of a novel stem cell production technology, today announced operating and financial results for the fourth quarter and full year ended December 31, 2019.

"We achieved a number of strategic priorities in 2019, including the IND approval to commence our first-ever trial in the U.S.," commented Dr. Shai Yarkoni, Chief Executive Officer."We plan to begin enrolling patients for this trial and completing the trial in Israel when the COVID-19 pandemic is mitigated. While these near-term events are value-enhancers, I believe that our recently announced prospective partnership with Canndoc could be a game-changer for Cellect and change our growth trajectory. It has the potential to significantly enhance our short and long term business prospects and shareholder value. As a player in the fast-growing pain management market, we would anticipate significant revenue opportunities already this year."

Recent Strategic Development

As previously announced, on March 4, 2020, the Company entered into a commercial binding Letter Of Intent (LOI) with Canndoc Ltd, a leading pharma grade medical cannabis pioneer and a wholly owned subsidiary of publicly-traded Intercure Ltd. (TASE: INCR),to acquire from Canndoc all rights to the use and sell Canndoc products for the reduction of opioid usage, including accumulated data, as well as on-going and pipeline of clinical trials. This commercial arrangement is subject to negotiation and approval by each company's board of directors and definitive agreements.

Additionally, the two companies signed a non-binding LOI for a full merger. Under preliminary details, Cellect will acquire from Intercure all of Canndoc outstanding shares, in exchange for additional Cellect ADRs to be in total ~95% (~93% on a fully diluted basis) of the merged company. The proposed merger is subject to independent valuation of both companies, fairness opinion by a third party, negotiation of a definitive agreement, approval of the agreement by the Company's Board of Directors and shareholders, internal approvals by Canndoc and Intercure, and customary closing conditions, including the approval of the IMCA (Israeli Medical Cannabis Agency). Upon the closing of the merger, Cellect and Canndoc will aim to fulfill all of the requirements to ensure the Company's ADRs and warrants continue trading on the Nasdaq Stock Market (Nasdaq) and, for this purpose, Intercure would commit to invest a cash sum of at least $3.0 million in any public offering that is undertaken by the Company, at a price of not less than $4.50 per ADR.

Based on the progress to date, the Company continues to expect the commercial and merger transactions will close in the second quarter of 2020.

Additional Operating Highlights:

Clinical Progress Update:

Due to the ongoing COVID-19 pandemic, the Company is experiencing clinical disruption such as:

The Company continues to take all the necessary precautions advised by global health officials to ensure the health and safety of its employees and partners. The Company is unaware of any impact on employees from pandemic related exposure or illness and is continuing to perform in-house research, including in the opioid/pain management area.

Fourth Quarter and Full Year 2019 Financial Results:

Balance Sheet Highlights:

For the convenience of the reader, the amounts have been translated from NIS into U.S. dollars, at the representative rate of exchange on December 31, 2019 (U.S. $1 = NIS 3.456).

About Cellect Biotechnology Ltd.

Cellect Biotechnology (NASDAQ: APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

The Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's intent regarding the future potential of Cellect's technology. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; and the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.

Cellect Biotechnology Ltd

Consolidated Statement of Operation

Convenience

translation

Twelvemonths

ended

Twelve months ended

Three months ended

December 31,

December 31,

December 31,

2019

2019

2018

2019

2018

Unaudited

Audited

Audited

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands, except share and pershare data)

Research and development expenses

3,508

12,122

13,513

2,571

4,040

General and administrative expenses

2,954

10,210

15,734

2,378

4,733

Operating loss

6,462

22,332

29,247

4,949

8,773

Financial expenses (income) due towarrants exercisable into ADS

(2,032)

(7,022)

(7,719)

998

(4,784)

Other financial expenses (income), net

433

1,498

(1,415)

129

(238)

Total comprehensive loss

4,863

16,808

20,113

6,076

3,751

Loss per share:

Basic and diluted loss per share

0.023

0.079

0.155

0.027

0.029

Weighted average number of sharesoutstanding used to compute basic anddiluted loss per share

212,642,505

212,6432,505

129,426,091

224,087,799

130,274,953

Cellect Biotechnology Ltd

Consolidated Balance Sheet Data

ASSETS

Convenience

translation

See the article here:
Cellect Biotechnology Reports Fourth Quarter and Full Year 2019 Results - BioSpace

Dublin, April 08, 2020 (GLOBE NEWSWIRE) -- The "Global Dental Partnering 2010-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Global Dental Partnering 2010 to 2020 provides the full collection of Dental disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Dental disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Dental deals. It also presents financial deal terms values for Dental deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Dental dealmaking trends.

In addition, a comprehensive appendix is provided with each report of all Dental partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Dental partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Dental technologies and products.

Analyzing actual contract agreements allows assessment of the following:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/u1um83

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the rest here:
Dental Partnering Deals Collection 2010-2020: Provides the Full Collection of Dental Disease Deals Signed Between the World's Leading Pharmaceutical...

EPS growth is an important number as it gives a suggestion of the future prospects of a company. It is usually expressed as a percentage and is then referred to as the EPS growth rate. Growth in EPS is an important measure of administration performance because it shows how much money the company is making for its investors or shareholders, not only because of changes in profit, but also after all the effects of issuance of new shares (this is especially important when the growth comes as a result of acquisition).

Vir Biotechnology, Inc., belongs to Healthcaresector and Biotechnologyindustry. The companys Market capitalization is $4.07B with the total Outstanding Shares of 264. On 06-04-2020 (Monday),VIRstock construct a change of 26.55 in a total of its share price and finished its trading at 36.7.

Profitability Ratios (ROE, ROA, ROI):

Looking into the profitability ratios of VIR stock, an investor will find its ROE, ROA, ROI standing at 0%, 0% and -41.9%, respectively. Return on assets (ROA) is a financial ratio that shows the percentage of profit a company earns about its overall resources. A performance measure used to estimate the efficiency of an investment or to compare the ability of some different investments. ROI measures the amount of return on an investment relative to the investments cost.

Earnings per Share Details of Vir Biotechnology, Inc.:

The EPS of VIRis strolling at -5.76, measuring its EPS growth this year at -443.3%. As a result, the company has an EPS growth of 3.3% for the approaching year.

Given the significance of identifying companies that will make sure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years.

We cant have sufficient maintenance the once will always replicate the difficult, but logically stocks that have grown earnings per allowance strongly in the subsequent to are a fine bet to keep on to take effect as a result.

Analysts mean target price for the company is $33.33 while analysts mean suggestion is 3.2.

A beta factor is used to measure the volatility of the stock. The stock remained 14.54% volatile for the week and 22.72% for the month.

Historical Performance In The News:

Taking a look at the performance of Vir Biotechnology, Inc.stock, an investor will come to know that the weekly performance for this stock is valued at 3.38%, resulting in a performance for the month at -19.69%.

Therefore, the stated figure displays a quarterly performance of 201.07%, bringing six-month performance to 0% and year to date performance of 191.85%.

P/S, P/E, P/C and P/B/ SMA50, SMA 200:

The price-to-sales is a valuation ratio that relates a companys stock price to its revenues. The price-to-sales ratio is a symbol of the value placed on each dollar of a companys sales or taxes. As of now, VIR has a P/S, P/E and P/B values of 501.93, 0 and 1.16 respectively. P/E and P/B ratios both are used on a regular basis by the investor to measure the value of the company and to get the right amount of the share.

Its P/Cash valued at 10.6. The price-to-cash-flow ratio is a stock valuation indicator that measures the value of a stocks price to its cash flow per share

What do you mean by simple moving average (SMA)?

A simple moving average (SMA) is an arithmetic moving average calculated by adding the closing price of the security for some time periods and then dividing this total by the number of time periods. Its distance from 20-days simple moving average is -0.26%, and its distance from 50 days simple moving average is 19.04% while it has a distance of 77.29% from the 200 days simple moving average. The companys distance from 52-week high price is 264% and while the current price is 264% from 52-week low price.

Read the original:
Data Shows Recession Fears May Be Overblown:: Vir Biotechnology, Inc., (NASDAQ: VIR) - NasdaqNewsFeed

For the readers interested in the stock health of Vir Biotechnology, Inc. (VIR). It is currently valued at $33.19. When the transactions were called off in the previous session, Stock hit the highs of $38.74, after setting-off with the price of $36.5. Companys stock value dipped to $32.15 during the trading on the day. When the trading was stopped its value was $29.00.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -55.74% during the 52-week period from high price, and 184.91% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.1 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 130.62%, having the revenues showcasing 140.86% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.21B, as it employees total of 229 workers.

During the last month, 3 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 22.19, with a change in the price was noted +19.48. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +146.80% for the period of last 100 days, recording 572,027 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 28.28%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 20.94%. In the last 20 days, the companys Stochastic %K was 11.97% and its Stochastic %D was recorded 11.37%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 130.62%. The shares increased approximately by 1.54% in the 7-day charts and went up by -15.45% in the period of the last 30 days. Common stock shares were driven by 140.86% during last recorded quarter.

Continue reading here:
This is to seal it as Vir Biotechnology, Inc. (VIR) shares are up 184.91% from its 52-week low - The InvestChronicle

CHICAGO, April 2, 2020 /PRNewswire/ --ARCH Venture Partnerstoday announced the closing of two new funds, ARCH Venture Fund X and ARCH Venture Fund X Overage, with a combined $1.46 billion to invest in transformative, early stage biotechnology companies.

ARCH Venture Partners Logo

"ARCH has always been driven to invest in great science to impact human health. There isn't a better illustration of our principles than our all-in battle against COVID-19. The healthcare revolution will be accelerated by the changes that are happening now and we are excited to continue to invest aggressively in risk takers doing truly transformational science," said co-founder and Managing Director Robert Nelsen.

ARCH will deploy Fund X and Fund X Overage to invest in early stage companies. While ARCH will frequently co-invest in a company with both funds, Fund X Overage will be utilized in fewer deals requiring larger investments. Limited partners include endowments, family offices, sovereign wealth funds and other institutional investors.

"Our companies bring cutting-edge science, tools and talent to bear in developing medicines for a wide range of diseases and conditions faced by millions. With these two new funds, we are continuing that work with urgency and a deep sense of purpose. We invest at all levels, whether it's fifty thousand dollars or hundreds of millions, so that each company and each technology has the best chance to advance and change the landscape," said Managing Director Kristina Burow.

Fund X and Fund X Overage follow ARCH Venture Fund IX and ARCH Venture Fund IX Overage, which closed in 2016 with a combined $1.1 billion. ARCH Venture Fund VIII and ARCH Venture Fund VIII Overage closed in 2014 with a combined $560 million.

"ARCH remains committed to our mission of the last 35 years, advancing the most promising innovations from leading life science and physical sciences research to serve the worldwide community by addressing critical health and well-being challenges. ARCH has been privileged to found, support and invest in groundbreaking new companies pursuing advancements in infectious disease, mental health, immunology, genomic and biological tools, data sciences and ways of reimagining diagnostics and therapies," said co-founder and Managing Director Keith Crandell.

Early stage ARCH investments have included Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, Receptos, Agios Pharmaceuticals, Vir Biotechnology, Sage Therapeutics, bluebird bio, Codiak Biosciences, Denali Therapeutics, GRAIL, Karuna Therapeutics, Beam Therapeutics, Lyell Immunopharma, Sana Biotechnology, Brii Biosciences, Twist Biosciences, Aviron, Ikaria, Gossamer Bio, Fate Therapeutics, Array Biopharma, Adolor, Quanterix, 908 Devices, Unity Biotechnology, Hua Medicine, deCODE Genetics, Homology Medicines and others.

In the battle against COVID-19, ARCH companies Vir Biotechnology, Alnylam Pharmaceuticals, VBI Vaccines, Brii Biosciences and Sana Biotechnology are currently working to develop COVID-19 therapeutics; Quanterix is advancing technology that can help with clinical testing needs and support clinical trial continuity; Twist Biosciences is advancing genomic and gene engineering tools used in COVID-19 therapeutic and vaccine development; and Bellerophon's inhaled nitric oxide (iNO) delivery system recently received emergency expanded access approval from the Food and Drug Administration for treatment of COVID-19.

Story continues

"ARCH is still willing to sit down with a scientist with a lab notebook to develop and translate great science into great companies. Fundamental science is what drives us and creating new diagnostics and disease modifying and curative therapies is what motivates us," said Managing Director Steve Gillis.

ARCH's Managing Directors include:

About ARCH Venture Partners:

ARCH Venture Partners invests in advanced technology companies and is one of the largest early stage technology venture firms in the United States. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories. ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market.

For more information, visit http://www.archventure.com.

Contact:Morgan Warnersmwarners@gpg.com 202-337-0808

View original content to download multimedia:http://www.prnewswire.com/news-releases/arch-venture-partners-announces-1-46-billion-raised-in-two-new-funds-to-invest-in-transformative-biotechnology-companies-301033707.html

SOURCE ARCH Venture Partners

View original post here:
ARCH Venture Partners Announces $1.46 Billion Raised in Two New Funds to Invest in Transformative Biotechnology Companies - Yahoo Finance

Today, well introduce the concept of the P/E ratio for those who are learning about investing. Well show how you can use Apex Biotechnology Corp.s (TPE:1733) P/E ratio to inform your assessment of the investment opportunity. Apex Biotechnology has a P/E ratio of 19.61, based on the last twelve months. That is equivalent to an earnings yield of about 5.1%.

Check out our latest analysis for Apex Biotechnology

The formula for P/E is:

Price to Earnings Ratio = Price per Share Earnings per Share (EPS)

Or for Apex Biotechnology:

P/E of 19.61 = NT$22.350 NT$1.140 (Based on the trailing twelve months to December 2019.)

(Note: the above calculation results may not be precise due to rounding.)

The higher the P/E ratio, the higher the price tag of a business, relative to its trailing earnings. All else being equal, its better to pay a low price but as Warren Buffett said, Its far better to buy a wonderful company at a fair price than a fair company at a wonderful price.

The P/E ratio indicates whether the market has higher or lower expectations of a company. As you can see below Apex Biotechnology has a P/E ratio that is fairly close for the average for the medical equipment industry, which is 18.3.

Its P/E ratio suggests that Apex Biotechnology shareholders think that in the future it will perform about the same as other companies in its industry classification. So if Apex Biotechnology actually outperforms its peers going forward, that should be a positive for the share price. Further research into factors such as insider buying and selling, could help you form your own view on whether that is likely.

Earnings growth rates have a big influence on P/E ratios. Thats because companies that grow earnings per share quickly will rapidly increase the E in the equation. And in that case, the P/E ratio itself will drop rather quickly. So while a stock may look expensive based on past earnings, it could be cheap based on future earnings.

Apex Biotechnology increased earnings per share by an impressive 19% over the last twelve months. And earnings per share have improved by 229% annually, over the last three years. So one might expect an above average P/E ratio. Unfortunately, earnings per share are down 16% a year, over 5 years.

The Price in P/E reflects the market capitalization of the company. So it wont reflect the advantage of cash, or disadvantage of debt. Hypothetically, a company could reduce its future P/E ratio by spending its cash (or taking on debt) to achieve higher earnings.

Such expenditure might be good or bad, in the long term, but the point here is that the balance sheet is not reflected by this ratio.

The extra options and safety that comes with Apex Biotechnologys NT$214m net cash position means that it deserves a higher P/E than it would if it had a lot of net debt.

Apex Biotechnology trades on a P/E ratio of 19.6, which is above its market average of 14.1. Its net cash position supports a higher P/E ratio, as does its solid recent earnings growth. So it does not seem strange that the P/E is above average.

Investors should be looking to buy stocks that the market is wrong about. If the reality for a company is better than it expects, you can make money by buying and holding for the long term. So this free report on the analyst consensus forecasts could help you make a master move on this stock.

Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with modest (or no) debt, trading on a P/E below 20.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Here is the original post:
Heres What Apex Biotechnology Corp.s (TPE:1733) P/E Is Telling Us - Simply Wall St

Theravance Biopharma Inc (TBPH) is around the middle of the Biotechnology industry according to InvestorsObserver. TBPH received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. Theravance Biopharma Inc also achieved a score of 64 in the Biotechnology industry, putting it above 64 percent of Biotechnology stocks. Biotechnology is ranked 12 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Theravance Biopharma Inc (TBPH) stock is trading at $21.24 as of 1:16 PM on Wednesday, Apr 1, a loss of -$1.87, or -8.09% from the previous closing price of $23.11. The stock has traded between $20.97 and $22.85 so far today. Volume today is low. So far 90,893 shares have traded compared to average volume of 463,876 shares.

To see InvestorsObserver's Sentiment Score for Theravance Biopharma Inc click here.

Read the original here:
Biotechnology Industry: Does Theravance Biopharma Inc (TBPH) Stock Beat its Rivals? - InvestorsObserver

The 88 rating InvestorsObserver gives to Trillium Therapeutics Inc (TRIL) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 100 percent of stocks in the Biotechnology industry, TRILs 88 overall rating means the stock scores better than 88 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 88 would rank higher than 88 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Trillium Therapeutics Inc (TRIL) stock is trading at $4.23 as of 1:51 PM on Monday, Apr 6, an increase of $0.57, or 15.57% from the previous closing price of $3.66. The stock has traded between $3.76 and $4.31 so far today. Volume today is less active than usual. So far 1,151,186 shares have traded compared to average volume of 3,800,958 shares.

To see InvestorsObserver's Sentiment Score for Trillium Therapeutics Inc click here.

See the rest here:
Industry Breakdown: Where Does Trillium Therapeutics Inc (TRIL) Stock Fall in the Biotechnology Field? - InvestorsObserver

The acquisition of GE Healthcare Life Sciences by Danaher Corporation creates a giant in contract manufacturing and development. While GE Healthcare Life Sciences, will retain its 7,000 staff and multinational operations, the company will change its name to Cytiva, combining its well-known brands and offerings KTA, Amersham, HyClone, MabSelect or Whatman with its new mother companys platform.

The mission of the newly created CDMO, which is set to generate US$3.3bn in annual revenues, is to grow in the expanding biologicals market. Emmanuel Ligner, President of Cytiva, said, "Our commitment remains to provide patients with life-changing therapies and we will continue to bring innovative technologies to market that improve our customers' productivity. The CDMO will not only help companies help outsource their biologics production but also intends to provide services to the scientific community.

According to Danaher, in 2019, more than 75% of FDA-approved biological therapies relied on Cytiva technology for manufacturing including the emerging cell and gene therapy market, a field conducting more than 1,000 regenerative medicine studies at global scale.

As the global demand for personalised medicines, and advanced biological therapies continues to grow, the company will rely on its huge capabilities in instrumentation, cell line and process development together with effective production and purification technologies. Cytiva announced it will continue to drive research collaborations, including with the Center for Advanced Biological Innovation and Manufacturing in Boston, Harvard, MIT, university hospitals and industry partners such as Fujifilm Diosynth Biotechnologies and Alexandria Real Estate Equities Inc.Cytiva's broad portfolio includes well-known brands such as KTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex and Xuri.

Read the original post:
GE renamed Cytiva upon take-over by Danaher - European Biotechnology

The Marine Biotechnology market report provides a detailed analysis of this business space. The market is analyzed in terms of production as well as consumption. Based on the production aspect, the report includes particulars pertaining to the manufacturing processes of the product, alongside revenue and gross margins of the respective manufacturers. The unit cost decided by the producers across various regions during the forecast period is also included in the report.

Additionally, the study comprises of insights regarding the consumption pattern. Information concerning the product consumption volume and product consumption value is mentioned in the document. The individual sale price along with the status of the export and import graphs across various regions are provided. Meanwhile, an in-depth analysis of the production and consumption patterns during the estimated timeframe has been given.

A summary of the geographical landscape:

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/36827

An overview of the product landscape:

An outline of the application spectrum:

A gist of the competitive landscape:

In a nutshell, the Marine Biotechnology market report encompasses details about the equipment, downstream buyers and upstream raw materials. Growth factors impacting this industry vertical in consort with the marketing strategies implemented by the manufacturers have been analyzed and provided in the research report. The Marine Biotechnology market study report also offers insights regarding the feasibility of new investment projects.

Report Objectives:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/36827

Continued here:
Outlook on the Marine Biotechnology Market to 2024 by Application, End-user and Geography - Express Journal

Investors might want to bet on PDS Biotechnology (PDSB), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.

Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.

Therefore, the Zacks rating upgrade for PDS Biotechnology basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock Prices

The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for PDS Biotechnology imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.

Harnessing the Power of Earnings Estimate Revisions

As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.

Earnings Estimate Revisions for PDS Biotechnology

This biotechnology company is expected to earn -$2.33 per share for the fiscal year ending December 2020, which represents a year-over-year change of 34.7%.

Analysts have been steadily raising their estimates for PDS Biotechnology. Over the past three months, the Zacks Consensus Estimate for the company has increased 15%.

Bottom Line

Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of PDS Biotechnology to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportEdge Therapeutics, Inc. (PDSB) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

The rest is here:
PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

On Monday, Shares ofVir Biotechnology, Inc., (NASDAQ: VIR), inclined/declined 36.70% and closed at $26.55 in the last trading session.

Arithmetic Moving Averages VIR:

Simple Moving Average (SMA) is easy to calculate and SMA20 one is principally looking at prime trends. The 50-day moving average is more responsive to price changes than the 200-day moving Whereas long-term trend followers generally use SMA200 and most shareholders will look for a cross up or down this average to means if the stock is in a bullish or bearish trend. SMA20 is the last stop on the bus for (ST) short-term traders. The Vir Biotechnology, Inc. having its distance from 20-days simple moving average is -0.26%, and its distance from 50-days simple moving average is 19.04%, while it has a distance of 77.29% from the 200-days simple moving average.

Working over theproductivity proportionsof business stock, the speculator will discover its ROE, ROA, ROI remaining at 0.00%, 0.00% and -41.90%, individually.

ATR remains at 8.38 while Beta component of the stock stands at 0.00. The beta component is used to check the eccentrics of the stock. The VIR stock remained 3.38% unpredictable for the week and -19.69% for the month.

Market capitalization is only an extravagant proclaim for a bright idea: it is the market estimation of an organizations remarkable offers. These Amount and numbers are found by taking the postscript cost and increasing it by the all outnumber of offers remarkable. Understanding the market top isnt merely sign if you nearly putting legitimately in stocks. It is additionally helpful for common reserve speculators, the same number of assets will list the normal or middle showcase capitalization of its property. As the name recommends, this gives the centre-ground of the stores value speculations, filling financial specialists in as to whether the reserve, for the most part, puts resources into large, mid-or little top stocks.

Vir Biotechnology, Inc.Target:

The EPS of the company is strolling at -5.76. The companys Market capitalization is $4.07BBillion.

As stocks have aP/S,P/EandP/Bestimations of 501.93, 0.00 and 1.16 separately. Its P/Cash is esteemed at 10.60.

Development in profit per offer is everything. The healthy future development in profit per share (EPS) is an amazingly significant factor in recognizing an underestimated stock. The effect of income development is exponential. As time goes on, the cost of a stock will typically go up in lockstep with its income (accepting the P/E proportion is steady). Hence stocks with higher profit development should offer the most elevated capital increases. Whats more, doubling-up the growth more than doubles the capital gain, due to the compounding effect.

Volume & Average Volume Shares:

Volume of the Vir Biotechnology, Inc. exchanged hands with 3694738 shares compared to its average daily volume of 815.24K shares. Total volume is the number of shares or deals that point towards the whole activity of a security or market for a same period.

Post Views: 175

Read more:
There are countless reason to get interested in these stocks: :Vir Biotechnology, Inc., (NASDAQ: VIR) - News Align

New Jersey, United States: Market Research Intellect has added a new research report titled, Animal Biotechnology Market Professional Survey Report 2020 to its vast collection of research reports. The Animal Biotechnology market is expected to grow positively for the next five years 2020-2026.

The Animal Biotechnology market report studies past factors that helped the market to grow as well as, the ones hampering the market potential. This report also presents facts on historical data from 2011 to 2019 and forecasts until 2026, which makes it a valuable source of information for all the individuals and industries around the world. This report gives relevant market information in readily accessible documents with clearly presented graphs and statistics. This report also includes views of various industry executives, analysts, consultants, and marketing, sales, and product managers.

Market Segment as follows:

The global Animal Biotechnology Market report highly focuses on key industry players to identify the potential growth opportunities, along with the increased marketing activities is projected to accelerate market growth throughout the forecast period. Additionally, the market is expected to grow immensely throughout the forecast period owing to some primary factors fuelling the growth of this global market. Finally, the report provides detailed profile and data information analysis of leading Animal Biotechnology company.

Animal Biotechnology Market by Regional Segments:

The chapter on regional segmentation describes the regional aspects of the Animal Biotechnology market. This chapter explains the regulatory framework that is expected to affect the entire market. It illuminates the political scenario of the market and anticipates its impact on the market for Animal Biotechnology .

The Animal Biotechnology Market research presents a study by combining primary as well as secondary research. The report gives insights on the key factors concerned with generating and limiting Animal Biotechnology market growth. Additionally, the report also studies competitive developments, such as mergers and acquisitions, new partnerships, new contracts, and new product developments in the global Animal Biotechnology market. The past trends and future prospects included in this report makes it highly comprehensible for the analysis of the market. Moreover, The latest trends, product portfolio, demographics, geographical segmentation, and regulatory framework of the Animal Biotechnology market have also been included in the study.

Ask For Discount (Special Offer: Get 25% discount on this report) @ https://www.marketresearchintellect.com/ask-for-discount/?rid=208205&utm_source=SI&utm_medium=888

Table of Content

1 Introduction of Animal Biotechnology Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Animal Biotechnology Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Animal Biotechnology Market, By Deployment Model5.1 Overview

6 Animal Biotechnology Market, By Solution6.1 Overview

7 Animal Biotechnology Market, By Vertical7.1 Overview

8 Animal Biotechnology Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Animal Biotechnology Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @ https://www.marketresearchintellect.com/product/%ef%bb%bfanimal-biotechnology-market-size-and-forecast/?utm_source=SI&utm_medium=888

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven FernandesMarket Research IntellectNew Jersey ( USA )Tel: +1-650-781-4080

Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Animal Biotechnology Market Size, Animal Biotechnology Market Growth, Animal Biotechnology Market Forecast, Animal Biotechnology Market Analysis, Animal Biotechnology Market Trends, Animal Biotechnology Market

Read the original:
Animal Biotechnology Market Size Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 - Science In Me